The indications for liver transplantation among patients with post-hepatitis B virus (HBV)-related cirrhosis have changed over the past 35 years. We reviewed the long-term results of 47 patients treated with liver transplantation for HBV-related cirrhosis. Patients were classified into 3 groups according to the perioperative regimen. In the initial experience, no immunoprophylaxis was adopted (no-IP; n=5). From 1988-1996, an immunoprophylaxis scheme was adopted (HBIg; n=16). From 1997-2007, we adopted the combination of lamivudine and HBIg (LAM-HBIg; n=26). We calculated the prevalence of serological reinfection and patient survival at 1 to 20 years, using the 3 regimens. The recurrence rate was 75% in the group of untreated patients; 30% in the HBIg group; and 9% in the LAM-HBIg group. The overall survival was 67% at 5 years, and 64% at 10 and 20 years. The long-term survival for each of the 3 therapeutic approaches, namely, for the patients who did not receive any treatment, for the HBIg group, and for the LAM-HBIg group, were 20%, 50%, and 84%, respectively. We suggest to use the LAM-HBIg combination.

Avolio, A. W., Nure, E., Pompili, M., Barbarino, R., Basso, M., Caccamo, L., Magalini, S., Agnes, S., Castagneto, M., Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches, <<TRANSPLANTATION PROCEEDINGS>>, 2008; (Luglio): 1961-1964 [http://hdl.handle.net/10807/13860]

Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches

Avolio;Alfonso Wolfango; Nure;Erida; Pompili;Maurizio; Barbarino;Raffaella; Basso;L; Magalini;Sabina; Agnes;Salvatore; Castagneto
2008

Abstract

The indications for liver transplantation among patients with post-hepatitis B virus (HBV)-related cirrhosis have changed over the past 35 years. We reviewed the long-term results of 47 patients treated with liver transplantation for HBV-related cirrhosis. Patients were classified into 3 groups according to the perioperative regimen. In the initial experience, no immunoprophylaxis was adopted (no-IP; n=5). From 1988-1996, an immunoprophylaxis scheme was adopted (HBIg; n=16). From 1997-2007, we adopted the combination of lamivudine and HBIg (LAM-HBIg; n=26). We calculated the prevalence of serological reinfection and patient survival at 1 to 20 years, using the 3 regimens. The recurrence rate was 75% in the group of untreated patients; 30% in the HBIg group; and 9% in the LAM-HBIg group. The overall survival was 67% at 5 years, and 64% at 10 and 20 years. The long-term survival for each of the 3 therapeutic approaches, namely, for the patients who did not receive any treatment, for the HBIg group, and for the LAM-HBIg group, were 20%, 50%, and 84%, respectively. We suggest to use the LAM-HBIg combination.
Inglese
Avolio, A. W., Nure, E., Pompili, M., Barbarino, R., Basso, M., Caccamo, L., Magalini, S., Agnes, S., Castagneto, M., Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches, <<TRANSPLANTATION PROCEEDINGS>>, 2008; (Luglio): 1961-1964 [http://hdl.handle.net/10807/13860]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/13860
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact